Skip to main content
. 2019 Mar 11;9(4):e01254. doi: 10.1002/brb3.1254

Figure 5.

Figure 5

Glibenclamide inhibits the activation of hemin‐induced nucleotide‐binding oligomerization domain‐like receptor with a pyrin domain 3 (NLRP3) inflammasome. (a) Western blot analyses show a significant decrease in NLRP3, ASC, caspase‐1, and cl‐caspase‐1 (P20) protein expression in b.End3 cells 24 hr after the hemin treatment. (b) Bar graphs summarize the data, presented as means ± SE, from three groups (n = 3, *p < 0.05, **p < 0.01)